ARS Pharmaceuticals, Inc. SPRY Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s additional paid-in capital?
- ARS Pharmaceuticals, Inc. (SPRY) reported additional paid-in capital of $416.62M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- ARS Pharmaceuticals, Inc.'s additional paid-in capital increased by 7.9% year-over-year, from $386.14M to $416.62M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s additional paid-in capital has grown at a -3.1% compound annual growth rate (CAGR), from $479.61M to $408.73M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.